Emily Tso

ORCID: 0009-0009-5287-8564
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Cholangiocarcinoma and Gallbladder Cancer Studies
  • Cancer, Lipids, and Metabolism
  • Lung Cancer Treatments and Mutations
  • Multiple and Secondary Primary Cancers
  • Radiomics and Machine Learning in Medical Imaging
  • Peptidase Inhibition and Analysis
  • Advanced Biosensing Techniques and Applications
  • Hepatocellular Carcinoma Treatment and Prognosis
  • Monoclonal and Polyclonal Antibodies Research
  • Cancer-related molecular mechanisms research
  • Cancer, Hypoxia, and Metabolism
  • HER2/EGFR in Cancer Research
  • Male Breast Health Studies
  • Cancer and Skin Lesions
  • Head and Neck Cancer Studies
  • Immune Response and Inflammation
  • Antibiotics Pharmacokinetics and Efficacy
  • Biological Research and Disease Studies
  • Ovarian cancer diagnosis and treatment
  • Gene expression and cancer classification
  • Radiopharmaceutical Chemistry and Applications
  • Breast Lesions and Carcinomas
  • Renal Transplantation Outcomes and Treatments
  • Advanced Proteomics Techniques and Applications
  • Silymarin and Mushroom Poisoning

University of California, Berkeley
2024

Cleveland Clinic
2000-2004

Abstract Altered lipid metabolism is a common hallmark of various cancers, including intrahepatic cholangiocarcinoma (ICC), highly lethal carcinoma that lacks effective treatment options. To elucidate the changes in ICC, we coupled expression firefly luciferase gene (FFL) to AKT1 (AKT-FFL) via an IRES linker, and then hydrodynamically injected mice with AKT-FFL Notch1 intracellular cytoplasmic domain (NICD) establish luciferase-positive ICC model. This model not only enabled us monitor...

10.1158/1541-7786.mcr-23-0389 article EN Molecular Cancer Research 2024-02-15

Recent reports from widely separated sources indicate a renewed interest in the etiology of primary splenomegaly with cirrhosis liver and anemia (Banti's disease). Gibson Fawcett have isolated streptothrix-like organism (Nocardia) spleen which they believe to be causative agent. Pinoy Nanta Algiers Emile-Weil, Gregoire Flandrin Paris others cultivated fungus, Aspergillus, high percentage spleens cases applied terms “splenic mycosis” “mycotic splenomegaly” disease. These views not been...

10.3181/00379727-26-4323 article EN Experimental biology and medicine 1929-03-01

<div>Abstract<p>Altered lipid metabolism is a common hallmark of various cancers, including intrahepatic cholangiocarcinoma (ICC), highly lethal carcinoma that lacks effective treatment options. To elucidate the changes in ICC, we coupled expression firefly luciferase gene (FFL) to <i>AKT1</i> (<i>AKT-FFL</i>) via an IRES linker, and then hydrodynamically injected mice with AKT-FFL <i>Notch1</i> intracellular cytoplasmic domain...

10.1158/1541-7786.c.7267993.v1 preprint EN 2024-06-04

<div>Abstract<p>Altered lipid metabolism is a common hallmark of various cancers, including intrahepatic cholangiocarcinoma (ICC), highly lethal carcinoma that lacks effective treatment options. To elucidate the changes in ICC, we coupled expression firefly luciferase gene (FFL) to <i>AKT1</i> (<i>AKT-FFL</i>) via an IRES linker, and then hydrodynamically injected mice with AKT-FFL <i>Notch1</i> intracellular cytoplasmic domain...

10.1158/1541-7786.c.7267993 preprint EN 2024-06-04

10764 Background: To report a unique case of papilloma the breast with metastases to axillary lymph node. Methods: Case and review literature. Results: 80 year old Caucasian male presented right gynacomastia 3 months duration. The lesion was resected. Pathology consistent intraductal hyperplasia no evidence malignancy. Subsequently, after 2–3 weeks mass noted in axilla. This resected found be node had pathological characteristics original papilloma. Conclusion: Solitary papillomas are...

10.1200/jco.2006.24.18_suppl.10764 article EN Journal of Clinical Oncology 2006-06-20

5516 Background: The development of a 2nd (or 3rd) primary malignancy (SPM) is well recognized problem in pts with SCHNC. Although the prognosis such not defined, SPM felt to be an important competing cause death. Methods: We retrospectively reviewed our registry 222 SCHNC treated definitive chemoradiotherapy (CRT) between 1989–2002, identify those SPM, and define their clinical characteristics outcomes. All received 4-day continuous intravenous 5-fluorouracil (1000 mg/m2/day) cisplatin (20...

10.1200/jco.2004.22.90140.5516 article EN Journal of Clinical Oncology 2004-07-15

9629 Background: Estrogen receptor (ER) and progesterone (PR) are important prognostic predictive factors for breast cancer patients (pts). Murine monoclonal antibodies (MuAb) currently used in immunohistochemistry (IHC) assays to determine ER/PR status. Rabbit (RAb) may have greater affinity human antigens than MuAb. We compared the concordance of MuAb- RAb-based IHC ER PR value these other pts with Stage I-III cancer. Methods: TMAs were produced from formalin-fixed paraffin-embedded tissue...

10.1200/jco.2004.22.90140.9629 article EN Journal of Clinical Oncology 2004-07-15

5014 Background: CA 125 has proven to be useful in predicting changes that affect prognosis and management of ovarian cancer; however, interpreting variations the tumor marker is still not well-defined. Our goal was further understand analytical variability a conventional hospital laboratory. Methods: Patients with or primary peritoneal cancer, who received active therapy at Cleveland Clinic Foundation from July 2003 December 2003, were included this IRB-approved study. A blood sample...

10.1200/jco.2004.22.90140.5014 article EN Journal of Clinical Oncology 2004-07-15

5014 Background: CA 125 has proven to be useful in predicting changes that affect prognosis and management of ovarian cancer; however, interpreting variations the tumor marker is still not well-defined. Our goal was further understand analytical variability a conventional hospital laboratory. Methods: Patients with or primary peritoneal cancer, who received active therapy at Cleveland Clinic Foundation from July 2003 December 2003, were included this IRB-approved study. A blood sample...

10.1200/jco.2004.22.14_suppl.5014 article EN Journal of Clinical Oncology 2004-07-15

5516 Background: The development of a 2nd (or 3rd) primary malignancy (SPM) is well recognized problem in pts with SCHNC. Although the prognosis such not defined, SPM felt to be an important competing cause death. Methods: We retrospectively reviewed our registry 222 SCHNC treated definitive chemoradiotherapy (CRT) between 1989–2002, identify those SPM, and define their clinical characteristics outcomes. All received 4-day continuous intravenous 5-fluorouracil (1000 mg/m2/day) cisplatin (20...

10.1200/jco.2004.22.14_suppl.5516 article EN Journal of Clinical Oncology 2004-07-15

Avery, R. K.1; Pohlman, B.2; Bolwell, Tso, E.1; Goormastic, M.4; Adal, K. A.1; Mendez, Z.2; Goldman, M.3; Mossad, S. B.1; Kalaycio, M.2; Capozzi, D.3; Schmitt, Andresen, S.2; Longworth, D. L.1 Author Information

10.1097/00007890-200004271-00251 article EN Transplantation 2000-04-01
Coming Soon ...